This year Absolute Antibody was the primary sponsor for Cambridge Healthtech Institute’s Inaugural Bispecific Antibody Pipeline congress in Washington, DC. The conference’s aim was to bring together ‘key opinion leaders including regulators, clinicians, and industry experts to deepen our understanding of bispecific therapeutics and exchange innovative ideas’.
As antibody engineering specialists and regular exhibitors at CHI events, we sent our Head of R&D Dr Catherine Bladen along to join in with the discussion.
“I thoroughly enjoyed this congress, with both the quality and quantity of cutting-edge research exceeding my expectations,” says Catherine. “It was great to be able to interact with the FDA and other regulatory bodies, and I was particularly excited to hear that whilst one therapeutic bispecific is currently FDA-approved for the clinic, at least ten more are expected to be approved next year. Now really is the time for antibody-based biologics.”
“This congress would be informative and rewarding for antibody developers, medical doctors, and also regulatory scientists. I’m sure the discussion will continue at PEGS Europe next month.”
Next month, our CSO Ian Wilkinson will be speaking at PEGS Europe, so don’t miss his talk: “Scaling Up and Scaling Out: Pushing the Boundaries of Transient Protein Production”. You can also get in touch to arrange a meeting, or just drop by booth #219 if you’re there.
We’ll be seeing you!
hubXchange | Antibody Therapeutics USA West
27th September 2022
San Fransisco, CA